Inside Gerresheimer: A $180 Million Factory Expansion Meets a €240 Million Impairment Storm
15.06.2026 - 00:01:31 | boerse-global.de
Gerresheimer is pressing ahead with a $180 million automation project at its Peachtree City site in Georgia, adding two fully automated pallet warehouses and real-time tracking for inhaler components. The expansion, which began in 2024, is a response to surging demand for medical devices. Yet the operational story is being overshadowed by a deepening accounting crisis that has left the company's audited financial statements in limbo.
The root cause is a series of improper revenue bookings. Gerresheimer recognized revenue for goods too early, a breach of IFRS rules. The fallout is severe: the company must correct €35 million in revenue for the 2024 financial year, and adjusted EBITDA will be roughly €24 million lower than previously stated. For 2025, the damage swells to impairments of up to €240 million. Without an audited annual report, many institutional investors have been forced to sit on the sidelines or reduce their positions.
Compounding the delay, a second external auditing firm is now reviewing prior-year transactions. Until that review is complete, the company cannot obtain a clean audit opinion — a condition that has already forced the cancellation of the annual general meeting and the first-quarter report.
Should investors sell immediately? Or is it worth buying Gerresheimer?
The legal front is also heating up. Shareholder protection group DSW is examining claims for damages against former board members. Meanwhile, the German audit oversight body APAS is investigating KPMG, the auditor that initially gave the flawed accounts an unqualified opinion. The cascade of problems has hammered the stock. Gerresheimer shares closed Friday at €25.14, down roughly 47% over the past twelve months and far off the 52-week high of €50.25.
To shore up its balance sheet, Gerresheimer is pushing ahead with the sale of its US subsidiary Centor Inc. Morgan Stanley is advising on the process, and the company reports a two-digit number of interested parties. A deal is targeted for 2026. While the divestiture would reduce debt, it would also weigh on the remaining group's margins, since Centor is a profitable unit.
On the financing side, the company has secured a temporary reprieve. Creditors holding €870 million in Schuldschein loans have agreed to waive certain leverage covenants until September 30, 2026. The extension provides breathing room, but the clock is ticking. The key date remains June 2025, when management hopes to finally publish the audited 2024 results. Only after that can the long-overdue half-year report and Q3 figures follow — scheduled for July 14 and October 15, respectively.
Failure to meet the June deadline would raise the risk of breaching loan agreements later in the year. The company's revenue target of €2.3 billion for 2025 is explicitly conditional on resolving the audit. The next few months will test whether Gerresheimer can bridge the chasm between its operational momentum and the corrosive effects of its accounting missteps.
Ad
Gerresheimer Stock: New Analysis - 15 June
Fresh Gerresheimer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
